PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence

• Published in: Oncotarget Vol. 7; no. 33; pp. 53837 - 53852
• Main Authors: Li, Yaqing, Li, Xiaoran, Li, Xiaoli, Zhong, Yali, Ji, Yasai, Yu, Dandan, Zhang, Mingzhi, Wen, Jian-Guo, Zhang, Hongquan, Goscinski, Mariusz Adam, Nesland, Jahn M, Suo, Zhenhe
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 16.08.2016
• Subjects: Aged; Gene Knockout Techniques; Glutamate Dehydrogenase - metabolism; Glutaminase - metabolism; Glutamine - metabolism; Humans; Male; Middle Aged; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Pyruvate Dehydrogenase (Lipoamide) - metabolism; Research Paper; PDHA1 gene knockout; GC-MS analysis; glutamine dependence; prognosis; metabolic reprogramming
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.10782

Alternative pathways of metabolism endowed cancer cells with metabolic stress. Inhibiting the related compensatory pathways might achieve synergistic anticancer results. This study demonstrated that pyruvate dehydrogenase E1α gene knockout (PDHA1 KO) resulted in alterations in tumor cell metabolism by rendering the cells with increased expression of glutaminase1 (GLS1) and glutamate dehydrogenase1 (GLUD1), leading to an increase in glutamine-dependent cell survival. Deprivation of glutamine induced cell growth inhibition, increased reactive oxygen species and decreased ATP production. Pharmacological blockade of the glutaminolysis pathway resulted in massive tumor cells apoptosis and dysfunction of ROS scavenge in the LNCaP PDHA1 KO cells. Further examination of the key glutaminolysis enzymes in human prostate cancer samples also revealed that higher levels of GLS1 and GLUD1 expression were significantly associated with aggressive clinicopathological features and poor clinical outcome. These insights supply evidence that glutaminolysis plays a compensatory role for cell survival upon alternative energy metabolism and targeting the glutamine anaplerosis of energy metabolism via GLS1 and GLUD1 in cancer cells may offer a potential novel therapeutic strategy.